Rentschler Biopharma is in the final stages of preparations to begin commercial production of CureVac’s COVID-19 Shot. The German contract drug manufacturer built a production site for CureVac’s Vaccine and intends to deliver at least 100 million doses per year. Despite some uncertainty over the vaccine’s approval status with the European Medicines Agency (EMA), CureVac and Rentschler are in joint discussions to streamline the beginning of the commercial production process. Rentschler is also helping Pfizer and BioNTech to purify and concentrate their COVID-19 drug substance. Rentschler also has processed 100 batched mRNA during the last year which is approximately 700 million doses of vaccines.
Read more here.
More on: News Regulatory